非小细胞肺癌患者外周血CD4＋ CD25＋ Foxp3＋调节性T细胞的研究

Study of CD4＋ CD25＋Foxp3＋ regulatory T cells in peripheral blood of non-small-cell lung cancer patients

目的 研究非小细胞肺癌患者外周血CD4＋ CD25＋ Foxp3＋调节性T细胞的水平并探讨其临床意义.方法 应用流式细胞术检测肺癌组和对照组外周静脉血CD4 CD25＋ Foxp3＋调节性T细胞含量,并分析其临床意义.结果 肺癌组患者外周血CD4＋ CD25＋ Foxp3＋调节性T细胞水平[CD4＋ CD25＋ T/CD4＋T为（14.42±1.22）％,CD4＋CD25＋Foxp3＋ T/CD4＋T为（5.34±0.45）％]明显高于对照组[CD4＋ CD25＋ T/CD4＋ T为（10.67±0.98）％,CD4＋ CD25＋Foxp3＋ T/CD4＋T为（3.98±0.68）％]（t=2.431、2.273,均P＜0.05）;肺腺癌CD4＋ CD25＋ Foxp3＋调节性T细胞水平[CD4＋ CD25＋ T/CD4＋T为（15.05±0.92）％,CD4＋ CD25＋ Foxp3＋ T/CD4＋T为（5.99± 0.38）％]较肺鳞癌[CD4＋ CD25＋ T/CD4＋T为（13.03±1.64）％,CD4＋ CD25＋ Foxp3＋ T/CD4＋T为（3.91±0.62）％]明显增高（t=2.264、2.109,均P＜0.05）,并且Ⅳ期肺癌患者外周血中CD4＋ CD25＋＋ Foxp3＋调节性T细胞的数量明显高于Ⅲ期肺癌患者（t=2.165、2.058,均P＜0.05）.结论 非小细胞肺癌患者外周血中CD4＋ CD25＋ Foxp3＋调节性T细胞的水平显著高于健康者,且与临床分期、病理类型密切相关,表明CD4＋ CD25＋ Foxp3＋调节性T细胞可能参与了非小细胞肺癌的发生与发展.

Objective To study the level of CD4＋ CD25＋ Foxp3＋ regulatory T cells in peripheral blood of non-small-cell lung cancer patients.Methods The ratio of CD4＋ CD25＋ Foxp3＋ T cells inperipheral blood of lung cancer group and control group were determined by flow cytometry.Its clinic significance was analyzed,Results The ratio of CD4＋ CD25＋ Foxp3＋ Treg cells [the ratio of CD4＋ CD25＋ T and CD4＋ CD25＋ Foxp3＋ T cells were （14.42 ± 1.22） % and （5.34 ± 0.45） %] inperipheral blood was higher in the non-small-cell lung cancer group than in control group [the ratio of CD4＋ CD25＋T and CD4＋ CD25＋Foxp3＋ T cells were （10.67 ±0.98）% and （3.98 ±0.68）%] （t =2.431,2.273,all P 〈 0.05）.It was also higher in adenocarcinoma [CD4＋ CD25＋ T/CD4＋ T to （15.05 ± 0.92） %,CD4＋ CD25＋ Foxp3＋ T/CD4＋ T to （5.99 ± 0.38） %] than squamous carcinoma [CD4＋ CD25＋ T/CD4＋ T to （13.03 ± 1.64） %,CD4＋ CD25＋ Foxp3＋ T/CD4＋ T to （3.91 ± 0.62） %] （t =2.264,2.109,all P 〈 0.05）,and stage IV higher than stage m （t =2.165,2.058,all P 〈 0.05）.Conclusion The level of CD4＋ CD25＋ Foxp3＋ Treg cells in peripheral blood of non-small cell lung cancer was significantly higher than that of healthy subjects,related with the pathological type and clinical stage.The CD4＋ CD25＋ Foxp3＋ Treg cells may participate in the occurrence and development of non-small cell lung cancer.